Advertisement

Topics

Odonate Therapeutics Announces Pricing of Initial Public Offering

20:55 EST 6 Dec 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the pricing of i...

Other Sources for this Article

Odonate Therapeutics, Inc.
John G. Lemkey, 858-731-8180
Chief Financial Officer
jlemkey@odonate.com

NEXT ARTICLE

More From BioPortfolio on "Odonate Therapeutics Announces Pricing of Initial Public Offering"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...